Navigation Links
Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose
Date:10/6/2010

Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From... -- EVRY, France, October 6, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Alternative Energies, Gas, Oil & Energy, Green Technology, Biotechnology, Chemical, New Products & Services Click to view news release full screen  

Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose

 

EVRY, France, October 6, 2010 /PRNewswire/ -- Global Bioenergies, located on the Genopole campus at Evry (France), announces the first prototype of its manufacturing process for the biological production of isobutene. It relies on the use of a bacterial strain harboring an artificial metabolic pathway created by the company.

Global Bioenergies announces that it has reached a key milestone in the development of its process for the transformation of renewable resources into gaseous isobutene (also called isobutylene or methylpropene). An initial series of bacterial strains were developed that can produce isobutene by transforming glucose.

Marc Delcourt, co-founder and CEO of the company, states, "We have achieved our goal to bioproduce isobutene in vivo ahead of target. We are now concentrating our efforts on increasing both the rate and scale of fermentation. We plan to carry out pilot plant tests prior to the industrial exploitation of the process. This phase will require new financial investment."

Philippe Marliere, co-founder and designer of the process, adds, "We have taught a bacterium to convert glucose to isobutene through an entirely novel process. The metabolic layout that we established passes by 3-hydroxy-isovalerate (also called 3-hydroxy-3-methylbutyrate). This chemical intermediate, which is absent from natural bacteria is, in turn, enzymatically converted into isobutene in our strains. The process is set up in accordance with the patent application filed in July 2008."

Jean-Marc Paris, professor at the EcoleSuperieure de Physique et de Chimie (Paris Tech) and a member of the Scientific Advisory Board, concludes, "This is the first time that an artificial metabolic pathway, which leads the production of a light olefin from renewable resources, has been designed and assembled in a micro-organism. These results set a precedent for the in-depth changes which the worldwide chemical industry will have to undergo in the 21st century."

Fuels, as well as a variety of polymers, representing a global market of $29b, can be manufactured from isobutene. Global Bioenergies is now focused on repeating this success with other molecules of the light olefin family, such as ethylene and propylene, each one associated with markets greater than $100b.

http://www.global-bioenergies.com

Press and public relations:

Benedicte.Robert@global-bioenergies.com - Phone: +33-1-64-98-20-50


'/>"/>
SOURCE Global Bioenergies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
2. Reportlinker Adds Global Synthetic Biology Industry
3. Reportlinker Adds Global Soft Tissue Allografts Industry
4. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
5. BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium
6. Diagenode Releases Two New Epigenetic Monoclonal 5-hmC Antibodies for Quantifying Global Hydroxymethylation
7. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
8. Medix Uses Globalpark to Glean Insights From Over 20,000 Opinion Leaders
9. Chiasma to Present at the UBS Global Life Sciences Conference
10. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
11. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):